Clinical Trial Success Uncertainty: The success of Summit's lead product, ivonescimab, hinges on the positive outcomes of ongoing and future clinical trials, and any failure could significantly delay or prevent product approval and commercialization.

Regulatory Approval Uncertainty: Despite potential positive clinical data, there is no guarantee that regulatory authorities will grant approval for ivonescimab or any other pipeline candidates, impacting market access.

Intense Market Competition: The oncology market is highly competitive, and Summit's potential products face strong competition from existing treatments and other companies developing new therapies, which could limit market share and pricing power.